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CObjectives: To compare cost-effectiveness modeling analyses of strat-
egies to prevent osteoporotic and osteopenic fractures either based on
fixed thresholds using bone mineral density or based on variable
thresholds including bone mineral density and clinical risk factors.
Methods: A systematic review was performed by using the MEDLINE
database and reference lists from previous reviews. On the basis of
predefined inclusion/exclusion criteria, we identified relevant studies
published since January 2006. Articles included for the review were
assessed for their methodological quality and results. Results: The lit-
erature search resulted in 24 analyses, 14 of them using a fixed-thresh-
old approach and 10 using a variable-threshold approach. On average,
70% of the criteria for methodological quality were fulfilled, but almost
half of the analyses did not include medication adherence in the base
case. The results of variable-threshold strategies were more homo-
geneous and showed more favorable incremental cost-effectiveness
ratios compared with those based on a fixed threshold with bone O
h
a
a
I
e
, 5093
al So
oi:10.1016/j.jval.2011.11.030ineral density. For analyses with fixed thresholds, incremental
ost-effectiveness ratios varied from €80,000 per quality-adjusted
ife-year in women aged 55 years to cost saving in women aged 80
ears. For analyses with variable thresholds, the range was €47,000 to
ost savings. Conclusions: Risk assessment using variable thresholds
ppears to be more cost-effective than selecting high-risk individuals
y fixed thresholds. Although the overall quality of the studies was
airly good, future economic analyses should further improve their
ethods, particularly in terms of including more fracture types, incor-
orating medication adherence, and including or discussing unrelated
osts during added life-years.
eywords: cost-effectiveness analysis, cost-utility analysis, modeling,
steoporosis.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Background
Osteoporosis is a disease characterized by low bone mass and
structural deterioration of bone tissue, leading to bone fragility
and an increased susceptibility to fractures, especially of the hip,
spine, and wrist [1]. A precursor of osteoporosis is osteopenia in
which bone mineral density (BMD) is lower than normal but not
yet osteoporotic. Many of these fractures require surgical repair or
replacement of the joint. While up to a fifth of patients with osteo-
porotic fractures of the spine are hospitalized, patients with hip
fractures are almost always hospitalized [2]. Because the risk of
fracture grows exponentially with age, population aging is ex-
pected to increase the socioeconomic burden from osteoporotic
fractures in the future. In Germany, for example, total annual ex-
penditures for hip fractures, which were €2.77 billion in 2003, may
increase to €3.85 billion in 2030 [3]. For 2050, the projected number
f patients with hip fractures is 6.3 million worldwide [2].
Prevention strategies for individuals at increased risk of osteo-
orotic fractures can be classified into two types: strategies for the
eriod when accelerated bone loss starts, as during perimeno-
ause, immobilization, and corticosteroid use, and strategies for
he period when bone loss or fracture has occurred [4]. Although
* Address correspondence to: Dirk Müller, Gleueler Street 176-178
E-mail: dirk.mueller@uk-koeln.de.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.ighly effective drug treatments for individuals at increased risk
re available, the identification of high-risk individuals is difficult
nd, as a result, preventive strategies often fail to be cost-effective.
n general, identification of high-risk individuals can be based on
ither a fixed threshold or a variable threshold.
Fixed-threshold analyses
To identify high-risk individuals, in 1994 the World Health Orga-
nization (WHO) established a definition of osteoporosis based on
BMD. BMD is considered an important predictive factor for osteo-
porotic fractures and is measured by densitometry [1]. Densitom-
etry results are usually reported as a T score, which is the number
of SDs between the value of an individual and the mean value of a
group of young adults of the same sex [5]. According to the criteria
of theWHO, osteoporosis is defined by a T score of2.5 or less and
osteopenia by a T score of less than 1 and greater than 2.5 SD
[1]. Most randomized controlled trials of pharmacological agents
to prevent fractures have used dual x-ray absorptiometry (DXA) at
the hip or the spine as the preferred method to select high-risk
individuals on the basis of BMD. Because treatment of individuals
selected bymethods other than DXA (e.g., quantitative ultrasound
5 Cologne, Germany.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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285V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 8 4 – 2 9 8[QUS])may not result in the same risk reduction, DXAhas been the
most common method used for measuring BMD [6].
There are many other factors besides BMD, however, that de-
termine fracture risk, for example, variability of bone microarchi-
tecture, liability to fall [7], or bone markers (i.e., serum and urine
markers of bone turnover) [8]. Because the correlation between
BMD in a person today and 15 years or more later is poor [9] and
because many fractures occur among persons with normal bone
density [10], screen-and-treat strategies based on BMD alone have
een either not cost-effective or cost-effective only within certain
anges of drug costs, age, and societal willingness to pay [11].
Therefore, researchers have included several prescreening tools
for the measurement of BMD.
Prescreening tools based on clinical risk factors (CRFs) such as
prior fracture or low body mass index can be used to estimate a
pretest probability of osteoporosis based on DXA as a reference
standard. Prescreening tools range from very simple tools such as
the Osteoporosis Self Assessment Tool, which is based on age and
weight only, tomore complex rules with arbitrary scoring systems
[12]. When evaluating the cost-effectiveness of several decision
rules, the additional costs per case detected of prescreeningwith a
decision rule were much lower than those of extending DXA to all
women older than 50 years (€118 vs. €327), even if themost expen-
sive decision rule was used [13].
Using a fixed threshold, selection of individuals depends on the
measurement of BMD on the basis ofWHO criteria of osteoporosis
and osteopenia [1]. For this review, analyses were considered as
fixed-threshold analysis if a fixed T score was used for selecting
ndividuals at high risk.
Variable-thresholds analyses
Since 2001 several models for calculating fracture risk by in-
cluding CRFs in the assessment have been further devised and
evaluated [14–17]. Researchers were increasingly aware how
RFs are interrelated, and they were able to calculate variable
hresholds for risks of fracture. Because these calculations are
ased on extensive data collection, and because it enables phy-
icians to calculate the risk of an event for bothmen andwomen
t different ages, this approach is similar to the Framingham
ardiovascular risk assessment [7]. By combining several con-
inuous (e.g., age) and dichotomous (e.g., immobility) variables
ith BMD, the gradient of risk (GR), which is the relative risk of
racture per SD change in BMD [18], increases compared with
MD alone.
The BMD T score required to reach a specific risk threshold
aries by age, gender, and the presence of additional CRFs. This
eads to improved sensitivity with only a moderate loss of speci-
city [19]. For this reason, the WHO and other organizations re-
ently have recommended using an individual’s 10-year risk of
racture to guide treatment decisions [20]. To improve patient as-
essment at a secondary-care level, an algorithm named the Frac-
ure Risk Assessment Tool (FRAX) was developed by a WHO task
orce. The CRFs used for the FRAX algorithm can be applied to
everal countries, and include a parental history of a hip fracture,
urrent smoking, alcohol intake of more than two units daily,
heumatoid arthritis, intake of oral glucocorticoids, and previous
ragility fracture [21]. Even CRFs alone may be of diagnostic value
or predicting fracture risks because age-specific gradient of risks
re similar to those of BMD alone [22]. The National Institute for
ealth and Clinical Excellence (NICE), however, is skeptical that
ecommendations about treatment should be based on absolute
isk as calculated by using FRAX because not all CRFs included in
he WHO algorithm are appropriate (i.e., there is no strong evi-
ence for a treatment effect on fracture risk for risk factors other
han low BMD, age, and prior fracture). In addition, absolute frac-
ure risk is not directly related to cost-effectiveness [23]. Hence,
he choice of CRFs is still a matter of debate.By using a variable threshold, the absolute long-term probabil-
ty of an osteoporotic fracture is estimated on the basis of age, sex,
nd CRFs, including, but not limited to, BMD [1]. While at younger
ages a variable threshold can be reached only with a substantially
decreased T score, at older ages it can be reached with a moder-
tely decreased T score. For this review, analyses were considered
s variable-threshold analysis if a variable T score was used for
electing individuals at high risk.
For the prevention of fractures, different antiosteoporotic
rugs are available. The commonly used drugs are bisphospho-
ates (e.g., alendronate or risedronate), which inhibit osteoclast-
nduced bone resorption [24]. Other treatment options include
ormone replacement therapy, parathyroid hormone, raloxifene,
trontium ranelate, or bazedoxifene. The efficacy of almost all
hese agents was evaluated on the basis of the WHO threshold of
steoporosis (T score 2.5). Exceptions are clodronate, which
lso belongs to the group of bisphosphonates, and bazedoxifene,
hich is a selective estrogen receptor modulator. Both were eval-
ated in women selected by the FRAX algorithm [25].
Several systematic reviews of cost-effectiveness analyses of
steoporosis screening published until 2006 compared different
xed-threshold strategies, the methods of evaluating these strat-
gies, and the results of these analyses [11,24,26,27]. Based on
hese reviews, recommendations were made to improve cost-ef-
ectiveness modeling; for example, future modeling studies
hould have a lifelong perspective due to the long-term effects of
steoporosis on costs, mortality, and quality of life, and they
hould consider case-finding costs. Since 2006 several cost-effec-
iveness analyses of screen-and-treat strategies for osteoporosis
ave been conducted, with an increasing number of them based
n variable thresholds. Building on previous reviews, the aim of
his systematic literature review was to provide an overview of
ost-effectiveness modeling analyses for osteoporosis since 2006
nd to compare the results of analyses based on a fixed-DXA
hreshold with those based on variable thresholds for selecting
igh-risk individuals.
In addition, several methodological aspects of the analyses
hat were considered as in need of improvement in previous re-
iews were evaluated [27]. As a result of inconclusive recommen-
ations, themajority of earlier conducted studies did not include a
ocietal perspective, and so important cost items were excluded
rom the analysis [27]. According to recommendations for health
conomic evaluations on osteoporosis treatment, a societal per-
pective should be carried out, which implies that unrelatedmed-
cal costs and nonmedical costs minus production gains should
lso be included in added years of life as recommended in guide-
ines for economic evaluations of interventions in osteoporosis
27–29]. This position is not taken up by NICE, whose position is
estricted to costs and cost savings for the National Health Service
nd personal social services, except for circumstances noted by
he Department of Health [30].
Because medication adherence was considered inconsistently
n previous analyses [11], our review aimed to evaluate how as-
ects of adherence were included in more recent analyses. More-
ver, the sources of data on utility were of interest because in earlier
tudiesepidemiologicaldataweremoreaccurately referenced toem-
irical studies than were data on costs and utilities [27].
Methods
Literature search
A literature search in the Medline database was performed to se-
lect cost-effectiveness models on screen-and-treat strategies of
osteoporosis published from January 2006 to November 2011.
Search terms (including MESH terms and text words) were costs
and cost analysis, decision making, osteoporosis, densitometry,
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286 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 8 4 – 2 9 8bone fracture, bone density, prevention of fall, and quantitative
ultrasound (the exact search terms are provided in a technical
appendix given in Supplemental Materials found at doi:10.1016/
j.jval.2011.11.030). In addition, the reference lists of three litera-
ture reviews were searched to capture articles that were not met
by the search terms [11,24,27].
From the list of titles and abstracts, only those articles that
fulfilled the following inclusion criteria were selected for detailed
assessment: cost-effectivenessmodeling studies (no reviews) that
were written in English, German, French, Spanish, Italian, or
Dutch and made comparisons of two or more strategies in which
the costs and effects for the prevention of fractures due to osteo-
porosis, osteopenia, or disease-related osteoporosis in women or
men were considered. Studies of fall prevention programs were
not included. To be considered for the review, the costs of case
finding and treatment had to be included in the analysis. Articles
were selected independently by two reviewers, and the results of
their literature searches were checked for agreement. To reach
consensus, any discrepancies between the reviewers were re-
solved by discussion.
Data extraction and quality assessment
Data of interestwere the characteristics of patients included in the
analysis, the method of selecting individuals at increased risk,
the type ofmodel used for the evaluation, the type of intervention,
the outcomes of interest, and the results/conclusions of the study.
Medication adherence was included in this review in terms of pri-
mary nonadherence (i.e., the situation in which patients are pre-
scribed a drug but they never fill the prescription) [25], nonpersis-
tence (i.e., the length of time from initiation to discontinuation of
therapy), and noncompliance (i.e., the extent to which a patient
acts in accordance with the prescribed interval and dose of a dos-
ing of regimen) [31]. In addition, information about the perspec-
tive, the time horizon of the analysis, the rate of discounting, costs
of added life-years, the duration of treatment, and the assessment
of uncertainty was extracted.
To assess the methodological quality of the cost-effectiveness
studies, the checklist by Philips et al. [32] was applied. This check-
list is a tool to detect the potential strengths and shortcomings of
pharmacoeconomic modeling studies. The checklist addressed
the following dimensions of quality: statement of decision prob-
lem/objective (S1), statement of scope/perspective (S2), rationale
for structure (S3), structural assumptions (S4), strategic compara-
tors (S5), model type (S6), time horizon (S7), disease states/path-
ways (S8), cycle length (S9), data identification (D1), datamodeling
(D2), data incorporation (D3), assessment of uncertainty (D4), in-
ternal consistency (C1), and external consistency (C2). As sug-
gested by Philipps et al. [32], the questions related to each dimen-
ion of quality were rated positive, negative, or unclear/not
pplicable (//0). If themajority of questions (50%) for a quality
imension were answered positive/negative, the dimension of
uality was rated with a positive/negative (/) point; otherwise,
he dimension was rated with 0. Multiple publications from the
amemodel were evaluated in the sameway. According to Philips
t al., the checklist is supposed to be used as a framework for
ritical appraisal without calculating an overall quality score for
hich no theoretical justification exists. To compare the method-
logical quality of the models, however, we presented the overall
umber of both positive and negative ratings across all dimen-
ions for each study.
Osteoporosis-specific quality criteria were derived from a ref-
rencemodel endorsed by the International Osteoporosis Founda-
ion (IOF) [27,33]. These relate to themodel structure (e.g., the type
nd number of health states) or the costs to be included in amodel
e.g., intervention costs, disease-related costs, and costs in added
ears of life).Results
Literature search
The literature search resulted in 748 potentially relevant articles
(Fig. 1). Based on titles and abstracts, 39 cost-effectiveness analy-
ses of strategies preventing osteoporotic or osteopenic fractures
were identified. Fifteen studies were excluded because they did
not fulfill the criteria for inclusion. Thus, the total number of stud-
ies for this analysis amounted to 24 analyses, 17 of them based on
cohort models (including 2 analyses based on a decision tree
model), 6 based on microsimulation (i.e., patient-level simula-
tions), and 1 based on discrete-event simulation. While 14 of the
analyses used a fixed-threshold approach (cohort models: 11, mi-
crosimulations: 2, discrete event: 1), 10 used a variable-threshold
approach (cohort models: 6; microsimulations: 4). Studies with a
fixed-threshold approach were conducted more often in the
United States (7), whereas those with a variable-threshold ap-
proach were mainly from the United Kingdom (5). Five studies
referred to osteoporosis in men or men and women. While the 14
fixed-threshold analyseswere based on 10 differentmodels, the 10
variable-threshold analyses were based on only four models, in-
cluding an updated version of the Sheffield Health Economic
Model for Osteoporosis [34,35] and a reference model recom-
mended by the IOF [27]. Two analyses evaluated a screen-and-
treat strategy for disease-specific osteoporotic fractures (i.e., the
cost-effectiveness of bisphosphonates in patients using glucocor-
ticoids or with localized prostate cancer) [36,37].
Type of intervention
For the majority of the analyses, bisphosphonates were used for
treatment (n 22). Therewere only a few studies evaluating treat-
Potentially relevant articles 
resulting from literature 
search: 
       748
Excluded based on titles and 
abstracts:
       709 
Fulltexts potentially relevant 
for the review: 
       39
Excluded from the review:  
Reason:  
- no cost-effectiveness study: 3 
-fall prevention for elderly: 2 
- treatment only: 10 
Number of articles considered 
for detailed assessment: 
       24 
Fig. 1 – Summary profile of the literature search.ment with raloxifene (n  3), hormone replacement therapy (n 
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287V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 8 4 – 2 9 82), parathyroid hormone (n  1), calcitonin (n  1), bazedoxifene
(n  1), or strontium ranelate (n  1).
Methodological quality of the analyses
On average, about 70% of the 15 dimensions of quality were rated
positive. For the majority of models, ratings were positive for
model structure (e.g., scope, rationale, structural assumptions, or
time horizon), collection of data (e.g., identification, incorporation,
or assessment of uncertainty), and consistency of the model (e.g.,
analysis/interpretation of the results). Analyses based on variable
thresholds showed higher quality than did those based on fixed
thresholds (81% vs. 61%). However, many models failed to provide
information about data identification and evidence for having tested
themodel before its use (internal consistency).While in 75% of anal-
yses based on a variable threshold, the results were tested in a prob-
abilistic sensitivity analysis, in two-third of fixed-threshold analyses,
sensitivity analysis was only deterministic. In addition, one quarter
of the models were based on fewer than three fracture states or a
time horizon of less than 30 years (Table 1).
Although consideration of the effects of noncompliance and
nonpersistence in the real world should be an integral part of
pharmacoeconomic evaluations [58], in many studies a definition
of compliance andpersistencewasnot provided. Eleven studies con-
sidered neither compliance nor persistence in the base case (with six
of these not even in the sensitivity analysis). When compliance or
persistence was included, data sources were based on randomized
controlled trials or observational data. In some cases, patients were
considered compliant above and noncompliant below an arbitrary
cutoff point. This ranged from 20% to 100%, often without evidence
for justification.Amongstudies that considerednonadherence in the
base case, five analyses (all of them based on fixed threshold) as-
sumed a linear decline in adherence [41,42,44,48,49], while seven
studies assumed a fixed nonadherence [38,39,45,50–54,].
In about 75% of the studies included in this review, unrelated
costs of added life-years, which would be necessary to account for
long-term care of patients [59], were not included. Disease-related
costs of added life-years, which are particularly important for hip
fractures, were included and described appropriately (e.g., by
mentioning the proportion of patients receiving long-term care in
nursing homes) in about 50% of the analyses.
Characteristics of the analyses
Several publications included in this review were based on a pre-
vious model; that is, the model used for the analysis referred to a
reference model or a model that was already published (fixed-
threshold models: 3; variable-threshold models: 8). While one
model [57] referred to a NICE model published in 2002, three mod-
ls [50,52,55] referred to a reference model recommended by the
OF [27]. The models from Schousboe et al. and Muller et al. were
ublished for the first time in 2007-2008 and resulted in three
8,41,46] and four [38,51,53,54] analyses, respectively. While about
wo-third of the analyses were based on Markov cohort models,
ne quarter was based onmicrosimulationmodels. In twoMarkov
odels, the no-memory assumption of the method was avoided
y using tunnel techniques for health states [25] or by creating
dditional health states [38,51,53,54]. About half of the analyses
ere conducted from a societal perspective.
In themajority of studies, a 5-year treatment with bisphospho-
ates, which have been shown to be highly effective in postmeno-
ausal women [24], was provided for individuals at increased risk.
n about 50% of the 20 analyses that used quality-adjusted life-
ears (QALYs), data on disutilities due to fractures were based on
atients from Sweden using the EuroQol five-dimensional ques-
ionnaire. While almost all analyses used states for hip, vertebral,
nd wrist fractures to estimate differences in effects, 13 analyses
lso considered other locations of fractures or side effects due toedication. When other locations of fractures were considered, in
ostmodels thiswas achieved by creating a state “other fracture” in
ddition to hip, vertebral, andwrist fractures (e.g., [8,25,41,46,50,52]).
n other models, additional fracture types were subsumed into hip,
ertebral, and wrist fractures (e.g., [57].
Information about diagnostic accuracy was either assumed to
e included in data on efficacy (because efficacy trials usually have
elected high-risk individuals based on BMD) or it was provided
hrough sensitivity and specificity (e.g., when patients were se-
ected by vertebral fracture assessment or QUS). In variable-
hreshold analyses, information derived from CRFs is supposed to
ncrease the sensitivity of fracture prediction without loss of
pecificity. For most models, however, this assumption was
onservatively assumed not to have an impact on risk reduction
21] because variable-threshold analysesmight also include nono-
teoporotic patients in which the efficacy of bisphosphonates is
ower [34]. Therefore, in these studies, a relative riskwas assumed,
hich was estimated for cohorts including patients with either
steoporosis or osteopenia. Increased efficacy by including CRFs
as assumed in only two German analyses that did not include
steopenic women [53,54].
CRFs included in variable-threshold analyses differed some-
hat. Risk factors such as multiple falls, immobility, or under-
eight have been included in the German analyses but were nei-
her included in the FRAX tool nor in the analysis of van Staa et al.
56] who used an additional set of CRFs including drug prescription
or the central nervous system, history of early menopause, and
he presence of several diseases (chronic obstructive pulmonary
isease, asthma, cerebrovascular events, heart failure, and in-
ammatory bowel disease). Several characteristics of the analyses
ncluded in this review are presented in Figure 2.
Results reported in the studies
Overall, the results of variable-threshold strategies weremore ho-
mogeneous and showed more favorable incremental cost-effec-
tiveness ratios compared with those based on a fixed threshold
with BMD. In contrast, the reported results did not appear to de-
pend on the type of model (i.e., cohort model or microsimulation).
For both types of analyses, the results weremore affected by factors
such as inclusion of compliance or characteristics of the cohort such
as age and presence/absence of prior fractures. For postmenopausal
women, incremental cost-effectiveness ratios varied from €80,000
er QALY in women aged 55 years to cost saving in women aged 80
ears when using a fixed threshold. For variable thresholds, the
ange was €47,000 (age 55 years) to cost saving (age 80 years).
Despite large discrepancies, the results of the studies included
n this review did not depend on the inclusion or exclusion of
edication adherence (neitherwhen comparing studies including
dherence with those not including nor in sensitivity analyses of
ingle studies estimating the potential effect of adherence on the
tudy’s cost-effectiveness ratio).
Analyses based on fixed thresholds
There were 14 fixed-threshold analyses, 2 of them based on micro-
simulations, 11 based on cohort models, and 1 based on discrete-
event simulation. Analyses differed markedly in their results be-
cause of differences in terms of methods and inclusion criteria for
high-risk individuals. Individuals were selected on the basis of BMD
measurement alone, BMD combined with CRFs, QUS, or serum and
urine markers of bone turnover (particularly bone resorption). The
populations evaluated varied considerably in terms of age and base-
line risk. This heterogeneity made comparisons of results difficult.
Overall, a strategy based on measurement of BMD alone in women
without fractures or in mixed-gender cohorts with and without a
fracture assuming real-world compliance has not been shown to be
cost-effective compared with no intervention at any age, thus con-
Table 1 – Methodological assessment.
Author (year) [Reference] Model type Dimension of quality Total

Total

Structure Data Consistency
Statement of
decision
problem
Statement of
scope/
perspective
Rationale
for
structure
Structural
assumptions
Strategies/
comparators
Model
type
Time
horizon
Disease
states/
pathways
Cycle
length
Data
identification
Data
modeling
Data
incorporation
Assessment
of
uncertainty
Internal
consistency
External
consistency
Fixed-threshold analyses
Muller and Gandjour (2011)
[38]
Cohort model           0     12 2
Ito et al. (2010) [37]          0   0  0 10 2
Ito et al. (2009) [39]    0      0  0    9 3
Ding et al. (2008) [40]        0  0 0 0 0  0 4 5
Schousboe et al. (2007) [8]          0      13 1
Schousboe et al. (2007) [41]          0      13 1
Schwenkglenks and Lippuner
(2007) [42]
       0  0  0    10 2
Schott et al. (2007) [43]          0  0 0   7 5
Pfister et al. (2006) [44]    0      0 0 0 0   6 4
Panichkul et al. (2006) [45]  0  0   0     0   0 3 7
Schousboe et al. (2006) [46]          0      12 2
Mobley et al. (2006) [47] DES       0   0   0   10 2
Hiligsmann et al. (2010) [48] Micro-simulation          0      13 1
Hiligsmann et al. (2008) [49]       0   0 0 0 0  0 6 3
Variable-threshold analyses
Borgström et al. (2010) [50] Cohort model    0            12 2
Ström et al. (2010) [25]             0   10 4
Mueller and Gandjour (2009)
[51]
               13 2
Kanis et al. (2008) [52]        0        13 1
Mueller and Gandjour (2008)
[53]
               13 2
Mueller et al. (2008) [54]                13 2
Iverga˚rd et al. (2010) [55] Microsimulation   0 0      0   0   9 2
van Staa et al. (2007) [56]          0      13 1
van Staa et al. (2007) [36]          0  0 0   10 2
Stevenson et al. (2007) [57]       0         14 0
DES, discrete event simulation; , item met demands; , item did not meet demands; 0, unclear or not applicable.
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289V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 8 4 – 2 9 8firming the results of earlier reviews [11]. When including CRFs, par-
ticularly prior fractures, or usingQUS as a prescreening tool formea-
surement of BMD, cost-effectiveness improved.
Among the three studies that included osteopenic patients
[8,42,46], one study included both osteopenic and osteoporotic pa-
tients [42]. The two analyses that included only osteopenicwomen
selected them on the basis of bone markers [8] or a prior vertebral
fracture [46]. When using bone markers in women aged 70 years,
the cost-per-QALY ratio (compared with no intervention) ranged
from $58,000 to $187,000 depending on the level of the bone
marker [8]. When using prior vertebral fractures (without knowl-
edge of BMD) to select high-risk women, the cost-per-QALY ratio
(compared with no intervention) ranged from $18,000 (in women
aged 60 years with a T score of2.4) to $77,000 (in women aged 80
years with a T score of 1.5) [46].
Four studies evaluated the cost-effectiveness of screening for
osteoporosis in men [37,39,41] or men and women [42]. Costs per
QALY ranged from $421,000 (age 70 years) to $34,000 (age 85 years)
in men without prior fractures and from $87,000 (age 70 years) to
$5000 (age 85 years) inmenwith prior fractures [36,39,42] (Table 2).
Analyses based on variable thresholds
There were 10 variable-threshold analyses: 4 of them based on
microsimulation and 6 based on a cohortmodel. The results of the
analyses based on variable thresholds were more homogeneous
compared with those based on fixed-threshold analyses. Almost
all analyses targeted postmenopausal women (with one exception
evaluating bisphosphonates inmale and female glucocorticoid us-
ers). The first model published in the period of interest for this
reviewwas influenced by economicmodeling undertaken by NICE
[60] and was an updated version of the Sheffield Health Economic
Model for Osteoporosis [34,35]. While Sheffield Health Economic
odel for Osteoporosis was based on cohort analyses using the
tandard techniques of decision analysis and state transition
 
 
cohort 
> 30 yea
societal
ﬁxed
fe
< 3
CUA
included in base cas
microsimulaon
≤ 30 years
health care
variable
male
≥ 4
CEA
excluded in base case   
0 5
model type
me horizon
perspecve
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number of 
fracture types
type of study
adherence
Fig. 2 – Model characteristics. CEA, cost-effectiveness analys
both females and males and thus are counted once in each
analyses, mortality and fracture probability were considered
calculated.§One study was based on discrete event simulatioodels, microsimulation was used in the updated model.Three analyses used CRFs, which were included in the FRAX
algorithm [25,50,55]. In addition to BMD, age, and a prior fracture,
these were low body mass index, a parental history of fracture,
long-term use of glucocorticoids, rheumatoid arthritis, smoking,
and alcohol consumption [20]. When including these CRFs in the
assessment of fracture risk in women with a prior fracture, the
cost-per-QALY ratio compared with no intervention ranged from
£27,000 to £7000 (age 50 years), from£17,000 to £3000 (age 65 years),
and from £11,000 to cost savings (age 80 years) with differences in
results of studies due to variations in drug prices and data on
efficacy [38,56]. For women without a prior fracture, the cost-per-
QALY ratio compared with no intervention ranged from £41,000 to
£15,000 (age 50 years), £25,000 to £7000 (age 65 years), and £18,000
to cost savings (age 80 years) [50,52].
The remaining analyses differed slightly from the FRAX algo-
rithm in terms of the CRFs used for selecting high-risk individuals.
Van Staa et al. used the criteria provided by the FRAX algorithm
but added drug prescriptions for the central nervous system and
the presence of diseases such as asthma or heart failure. In their
study, the cost-per-QALY ratio ranged from €270,000 (age 50 years)
to €9000 (age 80 years) in womenwithout a prior fracture and from
€38,000 (age 50 years) to cost savings (age 80 years) in womenwith
a prior fracture [56].
Four analyses [38,51,53,54] used amodel based on an algorithm
developed by the German osteology umbrella organization [61].
Estimates of fracture probabilities are very similar to the FRAX tool
and were based on prior fractures, a parental history of fracture,
immobility, underweight, smoking, and multiple falls. According
to the guideline by the German osteology umbrella organization,
DXA should be provided for women when there is a combined
10-year risk of 20% ormore for vertebral fractures (including those
who come to clinical attention and those who not) and hip frac-
tures. Drug treatment should be provided for women with a com-
bined risk of 30% or more for vertebral and hip fractures [61]. The
l
15 20 25
ber of Analyses
UA, cost-utility analysis. *Two studies reported results for
p.†Information was not provided in all studies.‡In two
less than 30 y, but lifetime costs for fractures weremode
rs
male
e
10
Num
is; C
grou
for
n.cost-per-QALY ratio of a strategy combining DXA and CRFs was
Table 2 – Cost-effectiveness analyses of selection strategies based on fixed thresholds using bone mineral density.
Author (year)
[reference]
Type of model Patients and method of selection (country) Diagnostic accuracy of
selection method (RR hip/
vertebral fracture)
Intervention vs. control
(outcome, year of costs)
Perspective,
horizon
Adherence (%) Results
Mueller and Gandjour
(2011) [38]
Cohort model
(based on [54])
Women aged 50–80 y with a prior fracture
selected by low BMD (T score of 2.5)
(GE)
Sensitivity/specificity: X-ray:
0.66/0.95 DXA: 0.54/0.91
RR: 0.46/0.53 (clinical trial
data)
Alendronate vs. no int.
(C/Q, € 2010)
Health insurance,
lifetime
Compliance rate (including
persistence) during
treatment period was
assumed to be 31%
BMD in women with a prior fracture is cost-effective
in all age groups. C/Q was less than €1000 in all
age groups. Compared with a variable-threshold
strategy, this strategy was less costly and less
effective: C/Q: €4600 (age 50 y), €19,800 (age 60 y),
€8700, €3400
Ito et al. (2010) [37] Cohort model Men with locally advanced or high-risk
localized prostate cancer (BMD: T score
of 2.5) (US)
RR: (clinical trial data) Alendronate vs. no int.
(C/Q, US $ 2008)
Societal, lifetime Rate of adherence: base
case: not included SA:
50%–100%
In patients with adjuvant deprivation therapy for
prostate cancer, BMD screening  selective
alendronate is cost-effective C/Q: $66,800
Ito et al. (2009) [39] Cohort model Men aged 70 y without a prior fracture
undergoing BMD screening or selected
by the Osteoporosis Self-Assessment
Tool (OST, cutoff  2) followed by
BMD (US)
Sensitivity and specificity of
the OST index: 0.28 and
0.98 RR: 0.73/0.36 (clinical
trial data)
Alendronate vs. no int.
(C/Q, C/LY, US $
2006)
Societal, lifetime Rate of adherence: 43% Selective BMD screening was more cost-effective
than immediate BMD screening and most cost-
effective when the lowest OST cutoff score of 2
was used. C/Q of immediate BMD screening was
$421,000. C/Q of prescreening with OST was
$86,500.
Ding et al. (2008) [40] Cohort model Women aged  55 y selected by low BMD
(T score of 2.5) with and without a
prior fracture (JP)
RR: 0.76/0.61 (clinical trial
data)
Risedronate  calcium
vs. no int. (C/Q, US
$2002)
Societal, 3 y Base case: not included SA:
compliance of 50%
assumed
For women without a vertebral fracture in the
previous 2 y, BMD scanning followed by
risedronate for those found to be osteoporotic had
a C/Q $100, 000 for all ages. For women  70 y
with a fracture, C/Q was $100,000
Schousboe et al.
(2007) [41]
Cohort model
(based on [58])
Men aged 65–85 y selected by DXA (T score
of 2.5) with and without a prior
fracture (US)
RR: 0.73/0.36 (clinical trial
data)
Alendronate vs. no int.
(C/Q, US $ 2004)
Societal, lifetime Primary nonadherence: 15%
Discontinuation of
treatment at year 1, year
2, and year 5: 65%, 60%,
55%
DXA followed by bisphosphonates for those with
osteoporosis may be cost-effective for men aged
 65 y with a self-reported prior clinical fracture
and for men aged 80–85 y with no prior fracture.
C/Q ranged from $129,700 (age 65 y) to
$33,700 (age 85 y) in men without prior fractures
and from $47,500 (age 65 y) to $4700 (age 85 y) in
men with prior fractures.
Schousboe et al.
(2007) [8]
Cohort model
(based on [58])
Women aged 70 y with DXA-based T
scores of 2.0 or 1.5 and with a high
(top quartile) or low (bottom three
quartiles) level of a bone turnover
marker (US)
RR: 1.0/0.5 (post hoc analyses
of osteopenic women
from clinical trials)
Alendronate vs. no int.
(C/Q, US $ 2004)
Societal, lifetime Base case: 100% SA:
persistence for only 18
mo, or compliance of
50%
Measurement of bone turnover: Markers can identify
a subset of postmenopausal women without
osteoporosis by BMD for whom bisphosphonate
therapy to prevent fracture is cost-effective. C/Q
ranged from $57,800 to $80, 600 (top quartile) and
from $136, 100 to $186,900 (bottom quartile).
Schwenkglenks and
Lippuner (2007)
[42]
Cohort model DXA in women and men aged 65–85 y,
treatment in those with a T score of
2.5 or, 2.5 but  1.0 and a prior
fracture (CH)
RR (T score  2.5): 0.5/0.5
RR (T score  2.5): 1.0/
0.7 (clinical trial data)
Alendronate vs. no int.
(C/Q, CHF 2005)
Societal, lifetime Persistence was assumed to
decline linearly from
100% to 65% during year
1 and from 65% to 45%
between end of year 1
and the end of
treatment (year 5)
BMD screening, followed by alendronate in women
with osteoporosis, or a prior fracture and
osteopenia, is cost-effective in Swiss
postmenopausal women after age 70 y. C/Q was
CHF 55,500 (age 65 y) to cost savings (age 85 y) in
women and CHF 176,700 (age 65 y) to CHF
48,300 (age 85 y) in men.
Schott et al. (2007)
[43]
Cohort model* DXA (T score  2.5) for all women aged 
70 y or for those with 1 or more clinical
risk factor (FR)
Sensitivity/specificity of DXA
in all women: 0.76/0.58
Sensitivity/specificity of
DXA with one or more
CRF: 0.75/0.54 RR: 0.65/
(clinical trial data)
Bisphosphonates vs. no
int. (C/LY gained per
hip fracture
avoided, year of
costs not stated)
Health-care
system, 10 y
As observed in the
underlying clinical trial
Compared with no screening, screening all women
with DXA is more cost-effective (€4200) than
screening only women with at least one risk
factor (€8300)
Mobley et al. (2006)
[47]
Discrete event
model
Women aged 65 y without prior fractures
and a DXA-based T score of 2.5 (US)
RR alendronate:
0.45/0.53 (clinical trial
data)
Alendronate, hormone
replacement
therapy, or
raloxifene vs. no int.
(C/Q, C/LY; US $
2002)
Health-care
system, until
90 y of age
As observed in the
underlying clinical trial
Among different drugs, screening and treatment
with alendronate was most cost-effective. C/LY
gained was $204,400 C/Q was 72,900.
(continued on next page)
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Table 2 (continued)
Author (year)
[reference]
Type of model Patients and method of selection (country) Diagnostic accuracy of
selection method (RR hip/
vertebral fracture)
Intervention vs. control
(outcome, year of costs)
Perspective,
horizon
Adherence (%) Results
Pfister et al. (2006) [44] Cohort model Women aged 65–85 y with and without a
prior fracture and a DXA-based T score
of 2.5 (US)
RR bisphosphonates:
0.5/0.5 (clinical trial data)
Bisphosphonates,
parathyroid
hormone,
calcitonin, or
raloxifene vs. no int.
(C/Q, US $ 2000)
Health-care
system, 5 y
Compliance rates for year 1
to year 5 were 80%, 60%,
40%, 35%, and 30%
C/Q of screening and treatment with
bisphosphonates compared with no int. was
$32,600.
Panichkul et al. (2006)
[45]
Cohort model* Women aged 4555 y with and without a
prior fracture selected by DXA, QUS,
CRFs, QUS followed by DXA, CRFs
followed by DXA (TH)
Sensitivity/specificity QUS:
0.84/0.32 DXA: 0.76/0.74
CRFs: 0.91/0.45 RR: 0.66/
(clinical trial data)
Hormone replacement
therapy  calcium
vs. no int. (C/hip
fracture prevented,
US $ 2004)
Societal, 30 y Compliance was assumed
to be 50%
CRFs and DXA were most cost-effective; further data
addressing the association between BMD in the
hip and hip fracture risk are needed. C/fractures
prevented were $79,900 (DXA alone)
$138,000 (QUS alone) $119,200 (CRFs) $62,800 (QUS
 DXA) $51,800 (CRFs  DXA)
Schousboe et al.
(2006) [46]
Cohort model Women aged 60–80 y with a T score of
2.5 and an additional prior vertebral
fracture (US)
Sensitivity/specificity of
vertebral fracture
assessment: 0.77/0.89 RR:
1.0/0.5–0.8 (post hoc
analyses of osteopenic
women without a
vertebral fracture) RR: 1.0/
0.5 (post hoc analyses of
osteopenic women with a
vertebral fracture)
Alendronate vs. no int.
(C/Q, US $ 2001)
Societal, lifetime Base case: not included SA:
adherence of 50%
assumed
C/Q of the vertebral fracture assessment strategy
compared with no int. ranged from $19,000 (for a
60-y-old woman with a T score of 2.4) to
$77,000 (for an 80-y-old woman with a T score of
1.5). C/Q of immediate treatment compared
with no int. in osteopenic women was $96,000
for all chosen T scores
Hiligsmann et al.
(2010) [48]
Microsimulation Women aged 55–75 y without a prior
fracture selected by DXA (T score 
2.5) (BE)
RR: 0.62/0.55 (clinical trial
data)
Alendronate vs. no int.
(C/Q, € 2006)
Health-care
system,
lifetime
Primary nonadherence:
11.6% Persistence: 42.5%
(6 mo) 18.1%, 13.9%, 7.2%
(1 y, 2 y, 3y)
Nonadherence with osteoporosis substantially
increases cost-effectiveness: C/Q (assuming real-
world adherence): €80,800 (age 55 y), €32,000 (age
65 y), and €10,600 (age 75 y) C/Q (assuming full
adherence): €40,500 (age 55 y), €16,900 (age 65 y),
and €1200 (age 75 y)
Hiligsmann et al.
(2008) [49]
Microsimulation Women aged 50–69 y selected by QUS
followed by DXA or immediate
treatment (BE)
Positive/negative predictive
value of QUS 0.66/0.22 RR:
0.62/0.57
Alendronate vs. no int.
(C/Q, €, year of costs
not stated)
Societal, lifetime Persistence 100% (year 1)
80%, 60%, 40%, and 20%
(year 2 to year 5)
QUS followed by DXA and immediate treatment can
be considered cost-effective. C/Q ranged from
€44,267 to €63,881 in case of real persistence and
from €38,112 to €48,320 in case of full persistence;
when taking into account CRFs, the C/Q improves
to €23,341 and €36,578, respectively.
BE, Belgium; C, costs; C/Q, costs per quality-adjusted life-year; CH, Switzerland; CRF, clinical risk factor; DXA, dual x-ray absorptiometry; FR, France; int., intervention; LY, life-year; QUS, quantitative
ultrasound; RR, relative risk; TH, Thailand.
* Decision tree analysis  cohort model.
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292 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 8 4 – 2 9 8below €20,000 in all age groups. Providing QUS as a pretest lowered
the incremental cost-effectiveness ratio [53,54]. To summarize the
results of fixed- and variable-threshold analyses, the inclusion of
CRFs or adding prescreening with QUS to the measurement of
BMD improves the cost-effectiveness of selecting high-risk indi-
viduals by using fixed thresholds. However, strategies based on a
variable threshold appear to be even more cost-effective than
fixed-thresholds strategies because the application of variable
thresholds enables clinicians to quantify a woman’s risk of frac-
ture more accurately even in younger women (Table 3).
Discussion
This literature review provides an overview of cost-effectiveness
analyses of screen-and-treat strategies for osteoporosis preven-
tion published since 2006. It compares the results of analyses
based on a fixed threshold using theWHOcriterion of osteoporosis
with those based on a variable threshold using the FRAX algorithm
or similar tools. The present analysis contains three major find-
ings: First, strategies based on variable thresholds showmore ho-
mogeneous results and are more cost-effective than strategies
with fixed thresholds. Second, using variable-threshold strategies,
treatment can be offered to younger women (i.e., age 50 years) at
an acceptable cost-effectiveness ratio. This is not possible using a
strategy based on fixed BMD thresholds because the fracture risk
of 50- to 65-year-oldwomen is too lowunless they have had a prior
vertebral fracture. Third, poor medication adherence is not rou-
tinely included in cost-effectiveness analyses of osteoporosis pre-
vention. However, when all aspects of nonadherencewere consid-
ered, cost-effectiveness ratios considerably increased.
The algorithms for the assessment of fracture risk were devel-
oped on the basis of population-based cohorts from Europe, North
America, Asia, and Australia. They allow estimation of the indi-
vidual fracture risk based on more aspects than T score, age, and
prevalent fracture [21]. When incorporated in health economic
analysis, the algorithms improve the precision in fracture-risk es-
timation beyond that previously possible [22]. The cost-effective-
ness studies based on variable thresholds in this review used
slightly different CRFs for their evaluation, and therefore imply
somewhat conflicting evidence of the CRFs’ contribution to frac-
ture risk. This lack of agreement includes several aspects: first,
there is evidence that factors such asmultiple falls, immobility, or
underweight are associated with higher fracture risk [63–65].
These have been included in the German guideline recommenda-
tion [61] but were included neither in the FRAX tool [20] nor in the
analysis of van Staa et al. [56]. Second, in contrast to FRAX and the
German guideline, van Staa et al. used an additional set of CRFs in-
cluding drug prescription for the central nervous system, history of
early menopause, and the presence of several diseases (chronic ob-
structive pulmonary disease, asthma, cerebrovascular events, heart
failure, and inflammatoryboweldisease) [56]. Basedondata fromthe
British General Practice Research Database, these have been shown
to be strongly related to fracture risk [66]. Finally, body mass index
was not included in the FRAX tool; however, it was included in the
German recommendation as a binary variable and in the van Staa
et al. analyses as a categorical variable (three categories) [56].
On assessing the methodological quality of the analyses, the
majority of dimensions were rated positive. Most analyses were in
line with recommendations provided in methods guidelines of
modeling research [32] as well as an osteoporosis-specific refer-
encemodel [27]. Suboptimal compliance and failure to persistwith
drug treatments, which are important determinants of therapeu-
tic nonresponse and are of potential economic significance [58],
however, were considered in only about half of the analyses.
Where compliance and/or persistence were included, definitions
were not provided, not justified, or varied between the analyses.
This oftenmeans that conclusions drawn from these analyses areof limited value. Some studies used a fixed rate of nonadherence
[37,38,45,50–54,], others assumed an increase during the treat-
ment period [8,42,44,48,49], and a third group considered nonad-
herence only in a sensitivity analysis [40,41,46,57]. In some stud-
ies, realistic assumptions (i.e., a decrease in adherence over time)
were provided either for persistence or for compliance without
justifying the exclusion of other aspects of adherence.
Only one analysis [48] included all aspects of nonadherence, that
is, noncompliance, nonpersistence, and primary nonadherence. An-
other analysis included nonpersistence and primary nonadherence
[41]. The remaining studies considered either compliance or persis-
tence or did not consider any aspect of nonadherence. When tested
in sensitivity analyses, adherence did not affect the results consider-
ably [38,42,46,51,53,54]. The conclusionof anegligible impact ofmed-
ication adherence on the cost-effectiveness ratio, however, is debat-
able because inmost studies not all aspects of adherencewere taken
into account. For interventionswith fixed case-finding costs, it could
be shown that the effect of nonadherence on cost-effectiveness can
be significant [67]. In a recent analysis of administrative claims (n
21,000), low adherence to osteoporosis pharmacotherapy was asso-
ciatedwith higher all-causemedical costs andmore all-cause hospi-
talizations [68]. Nevertheless, to date, the work in this field is sparse,
and, because of a lack of consensus on the quantitative measure-
ment of medication adherence, evidence of the real impact of de-
creased medication adherence is unclear.
In about one-third of variable-threshold analyses and in more
than half of fixed-threshold analyses, uncertainty was tested only
deterministically. This, however, does not provide enough insight
into the scale of decision uncertainty because uncertainty of indi-
vidual parameters may often be unlikely to change a decision [69].
According to the IOF [27,33], the fracture states to be included
in an osteoporosis model are hip, vertebral, wrist, and “other frac-
tures,” which provides the opportunity of including another frac-
ture considered to be important, but could also be used as a proxy
for all other osteoporotic fractures. While two studies were based
on hip fractures only [43,45], more than half of the studies in-
cluded fractures other thanhip, vertebral, orwrist fractures, either
by defining an own state “other fracture” as recommended by the
IOF or by summarizing fractures with similar costs and utilities
[56,57]. For example, disutilities associated with pelvis and other
femoral fractures resulted in their being grouped with hip fracture,
tibia fracture, and fibula fracture. Humeral shaft fractures were
groupedwith those of proximal humerus,while rib, scapula, clavicle,
and sternum fractures were groupedwith wrist fractures [57]. While
studies on alendronate in osteoporoticwomendid not showa signif-
icant reduction in fractures other than those of the hip or the wrist
[34], a studyon risedronate,whichalsobelongs to the classof bispho-
sphonates, reported a significant reduction of 39% in nonvertebral
fractures (defined as fractures of the clavicle, humerus, wrist, pelvis,
hip, or leg) [70]. Hence, the inclusion of fractures at other sites may
improve the cost-effectiveness of osteoporosis prevention. In line
with this, cost-effectiveness ratios in analyses with fewer fracture
types included [45,47] are higher compared with those in analyses
with more fracture types included (e.g., [25,57]).
As shown in previous reviews [11], adverse events are usually
not considered in osteoporosis models. Bisphosphonates, which
are often used for evaluating the cost-effectiveness of preventive
services for osteoporosis, are generally well tolerated and safe but
have been shown to occasionally cause serious adverse events such
as atrial fibrillation or osteonecrosis of the jaw [61]. The risk of ad-
verse events in patients with osteoporosis appears, however, to be
very low,withnoevidence fromepidemiologic studiesorprospective
randomized controlled trials of a causal association. Hence, the ex-
clusion of side effects in most models appears to be justified.
To evaluate cost-effectiveness, the majority of studies used
QALYs (n  20). About a half of these analyses, however, were
based on preference weights from a prospective observational
Table 3 – Cost-effectiveness analyses of selection strategies based on variable thresholds.
Author (year) [reference] Type of model Patients and method
of selection (country)
Diagnostic accuracy of
selection method (RR hip/
vertebral fracture)
Intervention vs. control
(outcome, year of costs)
Perspective, horizon Adherence (%) Results
Borgström et al. (2010) [50] Cohort model
(based on [27])
Women aged 50–80 y
selected by absolute
fracture risk using
the FRAX algorithm
(UK)
RR: 0.66/0.62 (based on post
hoc analysis from
clinical trials including
osteoporotic and
osteopenic women)
Risedronate vs. no int.
(C/Q, € 2006)
Health-care system, lifetime Persistence was assumed to
be 50% with the other 50%
discontinuing treatment
within year 1
C/Q ranged from £40,800 (age
50 y, T score  2.5 without
prior fracture), £26,600 (age
50 y, T score  2.5 with prior
fracture) and £38,400 (age
50 y, unknown BMD, parental
history of fracture) to £18,000,
£11,400, and cost savings (age
80 y), respectively.
Ström et al. (2010) [25] Cohort model
(based on [62])
Women aged 50–80 y
selected by absolute
fracture risk using
the FRAX algorithm
(SW)
RR: 0.89/0.61 (clinical trial
data)
Bazedoxifene vs. no int.
(C/Q, €2008)
Societal, lifetime As observed in the
underlying clinical trial
C/Q ranged from €80,000 (age
50 y) to cost savings (age 70 y)
in women with a parental
fracture (women with a prior
fracture: €66,000–€5400).
Compared with a fixed-
threshold approach, ICERs
were lower in women aged
 70 y.
Mueller and Gandjour
(2009) [51]
Cohort model
(based on [49])
Women aged 50–80 y
selected by absolute
fracture risk using
CRFs alone (GE)
Sensitivity/specificity: x-ray
(age 60 y): 0.66/0.95;
decision rule (age 70 y):
0.96/0.18; RR:
0.62/0.56 (clinical trial
data))
Alendronate vs. no int.
(C/Q, € 2006)
Health insurance, lifetime Compliance rate during
treatment period was
assumed to be 38%;
persistence was not
modeled
C/Q of CRFs vs. no int. is
€4600 (age 60 y), €21,200 (age
70 y), and €10,200 (age 80 y).
C/Q of DXA/CRFs compared
with CRFs alone is €20,200 in
women aged 60 y; in women
aged  70 y, DXA/CRFs
dominates CRFs.
Kanis et al. (2008) [52] Cohort model
(based on [27])
Women aged 50–80 y;
estimation of
individual
probabilities from
fracture and death
hazards based on
age, BMD (variable
thresholds), and
clinical
characteristics (UK)
RR: 0.62/0.56 (clinical trial
data)
Alendronate vs. no int. (C/Q,
year of costs not stated)
Health-care system, lifetime Persistence of treatment was
assumed to be 50% with
the other 50%
discontinuing treatment
within year 1
Alendronate was cost-effective
for the prevention of fracture
irrespective of age as was
treatment of women with a
prior fragility fracture
irrespective of BMD. C/Q
ranged from £14,700 (age 50 y,
T score  2.5 without prior
fracture), £14,600 (age 50 y,
unknown BMD, with prior
fracture), and £6700 (age 50 y,
T score  2.5 with prior
fracture) to cost savings (age
80 y) in women with a T score
of 2.5 or with a prior
fracture.
(continued on next page)
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Table 3 (continued)
Author (year) [reference] Type of model Patients and method
of selection (country)
Diagnostic accuracy of
selection method (RR hip/
vertebral fracture)
Intervention vs. control
(outcome, year of costs)
Perspective, horizon Adherence (%) Results
Mueller and Gandjour
(2008) [53]
Cohort model
(based on [54])
Women aged 50–80 y
selected by absolute
fracture risk using
DXA and CRFs with
QUS as a pretest
(GE)
Sensitivity/specificity: QUS:
0.79/0.58 DXA/CRFs:
0.60–0.66/0.72–0.75 RR:
0.45/0.52 (clinical trial
data)
Alendronate vs. no int. (C/Q, €
2006)
Health insurance, lifetime Compliance rate during
treatment period was
assumed to be 38%;
persistence was not
modeled
Cost-effectiveness of QUS and
DXA in sequence was
favorable in all age groups,
but DXA/CRFs increased the
number of QALYs at an
acceptable cost. C/Q of QUS 
DXA/CRFs was €3500 (age
50 y), €10,000 (age 60 y),
€4400 (age 70 y), and
€2000 (age 80 y). C/Q of DXA/
CRFs vs. QUS  DXA/CRFs was
€5300 (age 50 y), €60,800 (age
60 y), €14,900 (age 70 y), and
€3700 (age 80 y).
Mueller et al. (2008) [54] Cohort model Women aged 50–80 y
selected by absolute
fracture risk using
DXA and CRFs (GE)
Sensitivity/specificity: DXA/
CRFs: 0.60–0.66/0.72–0.75
RR: 0.45/0.52 (clinical
trial data)
Alendronate/risedronate/
teriparatide vs. no int.
(C/Q, € 2006)
Health insurance, lifetime Compliance rate during
treatment period was
assumed to be 38%;
persistence was not
modeled
C/Q of alendronate (DXA/CRFs):
€3900 (age 50 y), €16,600 (age
60 y), €6600 (age 70 y), and
€2300 (age 80 y). C/Q of
risedronate (DXA/CRFs):
€4600 (age 50 y), €20,500 (age
60 y), €7800 (age 70 y),
€3200 (age 80 y)
Iverga˚rd et al. (2010) [55] Microsimulation
(based on [27])
Women aged 55– 65 y
with increased risk
of fracture
(determined by
FRAX®) and breast
cancer (determined
by the Gail model*)
(US)
RR: /0.31 (clinical trial
data)
Raloxifene vs. no int. (C/Q, US
$ 2008)
Societal, lifetime Unclear In women aged 55 y, C/Q ranged
from $22,000 (risk of breast
cancer 5%, risk of fracture
15%–20%) to $110,000 (1%, 5%–
10%).
van Staa et al. (2007) [56] Microsimulation
(based on [36])
Women aged 50–90 y
randomly selected
from registry data
(estimation of
individual fracture
risks by using Cox
proportional
hazards models)
(UK)
RR: 0.67/0.59 (clinical trial
data)
Bisphosphonates vs. no int.
(C/Q, € 2003/2004)
Not stated, 10 y for
mortality and fracture
probability, lifetime costs
of patients with a
fracture
As observed in the
underlying clinical trial
Using a C/Q ratio of £30, 000,
bisphosphonates became
cost-effective for women with
a 5-y risk of 9.3% for
osteoporotic fractures and of
2.1% for hip fractures.
Including BMD in the risk
assessment, the C/Q gained
was £35,000 in women at age
60 y with a fracture history
and a T score of 2.5 (at age
80 y, this was £3000).
(continued on next page)
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Table 3 (continued)
Author (year) [reference] Type of model Patients and method
of selection (country)
Diagnostic accuracy of
selection method (RR hip/
vertebral fracture)
Intervention vs. control
(outcome, year of costs)
Perspective, horizon Adherence (%) Results
van Staa et al. (2007) [36] Microsimulation Oral glucocorticoid
users (male and
female) aged  40 y
(UK)
RR: 0.62/0.56 (clinical trial
data)
Bisphosphonates vs. no int.
(C/Q, € 2003/2004)
Not stated, 6 y for mortality
and fracture probability,
lifetime costs of patients
with a fracture
As observed in the
underlying clinical trial
C/Q of bisphosphonates during
intake of glucocorticoids
ranged from £41,000 in
women aged 60 y (men
£40,000), £17,000 in women
aged 60–79 y (men £43,000) to
£5000 in women aged 80 y
(men £35,000). Patients with
rheumatoid arthritis had
comparatively better cost-
effectiveness, given higher
fracture risk and better life
expectancy.
Stevenson et al. (2007) [57] Microsimulation
(based on
[34,35])
Women aged 50–80 y
selected by absolute
risk of fracture
using DXA and
CRFs (UK)
0.63/0.56 (clinical trial data) Strontium ranelate vs. no int./
alendronate (C/Q, € 2003/
2004)
Health-care system,
lifetime†
Base case: not included; SA:
no intake of drugs but
costs for 1 mo
Strategies that are cost-effective
at a threshold of £30,000 per
QALY are as follows: 50–69 y:
no screening is cost-effective
70–74 y: DXA in those with
one or more CRF and
alendronate at a T score of
2.8 (one CRF), 2.3 (two
CRFs), and 1.7 (three CRFs)
75–79 y: treat immediately
(three CRFs), DXA and
alendronate at a T score of
3.0 (0 CRFs), 2.3 (one CRF),
and 1.5 (two CRFs) 80 y:
treat immediately (two or
more CRFs), DXA in those
with 0 (1) CRFs and treat at a T
score of 2.3 (1.5). Using a
C/Q ratio of £20,000, the total
net benefit of a screen 
alendronate strategy was
£0 (age 50–69 y), €29 m (age
70 y), €122 m (age 75 y), and
€492 m (age 80 y).
C costs; C/Q costs per quality-adjusted life-year; CRF, clinical risk factors; DXA, dual x-ray absorptiometry; GE, Germany; ICER, incremental cost-effectiveness ratio; int., intervention;m,million;
QUS, quantitative ultrasound; RR, relative risk, SA, sensitivity analysis; SW, Sweden.
* A computer-based algorithm to estimate a woman’s 5-y risk of invasive breast cancer.
† The model simulates the initial 10-y period, where it is assumed that the intervention influenced fracture rates, and a subsequent period where the quality-adjusted life-years associated with
additional survival were incorporated.
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296 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 8 4 – 2 9 8study conducted in Sweden [71]. For measuring the loss of quality
of life from fractures adequately, the use of country-specific utili-
ties is recommended. Furthermore, it is important to estimate the
QALY level before the fracture based on a large sample size with a
sufficient long-term follow-up [72]. Both aspects did not apply to
the Swedish study, which makes many analyses building on this
study susceptible to bias.
An important limitation of this analysis is the checklist used
for the assessment of methodological quality of the studies. The
expert advisory group that developed the checklist [32] noted that,
in general, the checklist would be a useful tool for evaluating a
model’s quality, although it is too general to pick up on the specific
nuances of each model. Therefore, in accordance with the check-
list, we did not provide an overall score or ranking of the analyses.
Future research
Because of the above-listed limitations of the models, the next
step should be identifying methodological key issues that may
strongly affect a model’s cost-effectiveness ratio. This has to be
done carefully because themodels differ in numerous aspects and
a more or less favorable cost-effectiveness ratio almost always
results from multiple reasons. For example, the exclusion of frac-
ture types with potential benefit from the intervention or the in-
clusion of medication persistence and compliance do not neces-
sarily lead to an unfavorable cost-effectiveness ratio and vice
versa. To improve methodological standards and, particularly, to
make models more comparable, however, the following aspects
should be addressed.
First, the effect of different aspects of medication adherence
needs to be further evaluated. In this review, many studies either
used one single measure (compliance or persistence) or ignored
medication adherence completely. Because Hiligsmann et al. [48]
ould show that the cost-effectiveness ratio might be affected by
ny aspect of adherence, future analyses should incorporate these
spects. Although medication adherence has been evaluated in
ultiple studies, differences in methodology and patient demo-
raphics resulted in wide variations in medication adherence
73,74], requiring additional research in this field.
Second, because of contradictory evidence, modeling recom-
endations do not specify which costs to include in added life-
ears. These costs are associated with treatment because it ex-
ends the patient’s life. A controversy exists regarding whether
urvivor consumption costs should be included in cost-utility
nalyses [75]. Several researchers have argued that if treatment
esults in prolonged life because a condition has been cured or
arly disease has been avoided, then the cost of treating later dis-
ases that would not otherwise have arisen must be considered
75–78]. Still, this view has not been adopted by a number of inter-
ational pricing/reimbursement agencies and most cost-effec-
iveness analyses of osteoporosis prevention included in this re-
iew. Therefore, authors who follow the guidance by the pricing/
eimbursement agency in their country should not be criticized for
xcluding some or all survival costs.
The inclusion of these costs, however, may affect the results of
cost-effectiveness analysis significantly as shown in an eco-
omic evaluation of strontium ranelate in the treatment of osteopo-
osis where the cost-effectiveness ratio increased bymore than 40%
hen including costs in added life-years [79]. Based on the analyses
ncluded in this review, the cost-effectiveness ratios of studies that
ave included both osteoporosis-related and osteoporosis-unrelated
osts of added life-years were not significantly higher than those of
tudies that excluded them. Because the extent to which costs in
dded life-years may affect the cost-effectiveness ratio appears to
epend on the methods and data claims used for calculating these
osts, this issue should be further evaluated. Until consensus for this
uestion is reached, osteoporosis-unrelated costs in added years of
ife should be included in a sensitivity analysis.Third, future analyses should include all long-term costs re-
lated to fractures, particularly hip fractures. Although the long-
term costs of hip fractures are well documented, these costs were
not included or were referenced without providing details of spe-
cific cost components in many studies. For long-term costs of ver-
tebral fracture, improved documentation of the related costs is
needed because the chronic nature of these fractures implies sig-
nificant long-term costs [60].
Fourth, the contribution of different CRFs to the absolute frac-
ture risk needs to be further evaluated. In variable-threshold anal-
yses, the CRFs used for selecting high-risk individuals differed
slightly. Moreover, only few prospective cohort studies have eval-
uated CRFs such as muscle strength, gait, balance, or history of
falls. Recent data suggest that the tendency to fall, which is not
included in the FRAX tool, is a stronger predictor of fractures than
is lowBMD [80]. Because the reasons for fall aremultifactorial (e.g.,
oversedation with drugs, impaired balance, hearing or neurologi-
cal problems), it should be evaluated how these aspects are inter-
related. To date,measurement of variable thresholds still does not
allow estimating how muscles, nerves, and bones function as a
unit for coordination, mobility, balance, and strength [7].
Fifth, economic analyses usually consider hip, wrist, and clin-
cal vertebral fractures. These comprise themost common sites of
steoporotic fracture but, nevertheless, exclude fractures at other
ites, such as pelvis, distal femur, humerus, rib, and tibia. Al-
hough some researchers argue that this may be offset by the as-
umption that all fractures at an included site are due to osteopo-
osis [60], future cost-effectiveness analyses should include at
east pelvis and distal femur fractures, which almost always result
n inpatient treatment.
Sixth, more direct comparisons between fixed- and variable-
hreshold approaches are necessary. To date, there is only one
irect comparison, indicating an additional gain of quality of life at
cceptable costs with variable thresholds [38].
Seventh, formeasuring the loss of quality of life from fractures,
country-specific utilities should be estimated on the basis of large
sample sizes with sufficient long-term follow-up [71].
Finally, except for bazedoxifene and clodronate, the efficacy of
antiosteoporotic agents has been shown only in patients selected
by low BMD [25]. Because for many agents the risk reduction of
patients selected by variable thresholds (including patients above
and below the threshold of osteoporosis) is unclear, most eco-
nomic evaluations based on variable thresholds conservatively as-
sume that drug efficacy equals that of a group including both os-
teoporotic and osteopenic patients; this may have led to an
underestimation of drug efficacy in these studies because os-
teopenic patients with CRFs may also benefit. To date, there is
contradictory evidence whether individuals selected for treat-
ment on the basis of CRFs alone benefit from treatment or not.
While in most trials efficacy could be shown only in patients se-
lected by BMD, in some efficacy trials pharmacological interven-
tions with bisphosphonates have been shown to be effective in
patients receiving glucocorticoids orwith a prior vertebral fracture
[81–83]. Because the efficacy ofmany drugs in patients selected by
variable thresholds is still unclear, direct comparisons should be
performed between the different selection methods, that is, ran-
domized drug trials inwhich patientswill be selected by either low
BMD alone or the calculation of variable thresholds.
Conclusion
The shift from selecting individuals by fixed-BMD threshold to
selecting them by variable thresholds yields results that indicate
more favorable cost-effectiveness ratios. Variable-threshold as-
sessment can be used to select individuals for whom testing with
expensive DXA would be appropriate; that is, DXA would be indi-
cated only in individuals with an increased risk of fractures. Mov-
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297V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 8 4 – 2 9 8ing away from BMD alone means that in each age group those
identified to be at increased risk have a higher probability of ben-
efiting from treatment. Because there is a lack of evidence in the
contribution of several important CRFs, these have not been in-
cluded yet in tools for quantifying variable thresholds. While epi-
demiological studies should be performed to evaluate how these
CRFs contribute to fracture risk, economic analyses should further
improve their methods. Particularly, models should include more
fracture states, different aspects of medication adherence, and
country-specific preference weights based on high-quality data.
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